Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals Corporation Receives FDA Approval for ZIMHI

10/18/2021 | 07:30am EST

Adamis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose. Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose. It works by blocking or reversing the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl. According to statistics published by the Centers for Disease Control and Prevention (CDC), drug overdoses resulted in approximately 96,779 deaths in the United States during the 12-month period ending March 2021, which was a 29% increase over the prior 12-month period. Drug overdoses are now the leading cause of death for Americans under age 50, with more powerful synthetic opioids, like fentanyl and its analogues, responsible for the number of those deaths.


© S&P Capital IQ 2021
All news about ADAMIS PHARMACEUTICALS CORPORATION
12/02Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Highe..
AQ
12/01Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Highe..
AQ
12/01Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Highe..
CI
11/23ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
11/23Adamis Regains Nasdaq Listing Compliance by Filing Late Quarterly Reports; Stock Slides
MT
11/23Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
GL
11/23Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
GL
11/22ADAMIS PHARMACEUTICALS : Announces Third Quarter 2021 Financial Results and Provides Corpo..
PU
11/22Adamis Pharmaceuticals Reports Increased Nine-Month Revenues From Epinephrine Sales
MT
11/22ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Financials (USD)
Sales 2021 10,2 M - -
Net income 2021 -34,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,84x
Yield 2021 -
Capitalization 102 M 102 M -
Capi. / Sales 2021 9,95x
Capi. / Sales 2022 10,4x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,68 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION40.55%102
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641